Fennec Pharmaceuticals Inc. (FENC) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 7 Buy.
The consensus price target is $18.00, representing an upside of 188% from the current price $6.25.
Analysts estimate Earnings Per Share (EPS) of $-0.07 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.02 vs est $-0.07 (beat +77.7%). 2025: actual $-0.36 vs est $-0.13 (missed -178.2%). Analyst accuracy: 0%.
FENC Stock — 12-Month Price Forecast
$18.00
▲ +188.00% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Fennec Pharmaceuticals Inc., the price target is $18.00.
The average price target represents a +188.00% change from the last price of $6.25.
FENC Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Fennec Pharmaceuticals Inc. in the past 3 months
EPS Estimates — FENC
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.02
vs Est –$0.07
▲ 349.0% off
2025
Actual –$0.36
vs Est –$0.13
▼ 64.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — FENC
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.048B
vs Est $0.043B
▲ 10.4% off
2025
Actual $0.045B
vs Est $0.046B
▼ 0.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
